Carisma Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $3,729 | $3,653 | $3,385 |
Gross Profit | 3,729 | 2,984 | 3,385 | |
EBITDA | -8,673 | -17,186 | -12,407 | |
EBIT | -9,334 | -17,855 | -13,144 | |
Net Income | -9,774 | -9,266 | -17,635 | -12,702 |
Net Change In Cash | 0 | 3,729 | 3,653 | 3,385 |
Free Cash Flow | -5,904 | -10,067 | -8,352 | -13,020 |
Cash | 1,999 | 7,740 | 17,909 | 26,881 |
Basic Shares | 41,788 | 41,771 | 41,456 | 41,544 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $19,632 | $14,919 | $9,834 | $26,544 |
Gross Profit | 16,278 | -59,206 | 3,744 | 26,459 |
EBITDA | -58,825 | -85,894 | -51,991 | -40,112 |
EBIT | -62,179 | -88,731 | -58,081 | -40,197 |
Net Income | -60,477 | -86,879 | -61,226 | -40,784 |
Net Change In Cash | 19,632 | 14,919 | 9,834 | 26,544 |
Free Cash Flow | -60,040 | -82,309 | -12,226 | -39,199 |
Cash | 17,909 | 77,605 | 24,194 | 28,551 |
Basic Shares | 41,456 | 33,524 | 40,256 | 9,116 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.12 |
2025-03-31 | -$0.42 |
2024-12-31 | -$0.42 |
2024-09-30 | -$0.31 |
